NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL.
Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
Dates: December 3-4, 2024
Location: Florida Atlantic University, Boca Raton, FL
Presentation Day and Time: Wednesday, December 4, 2024, at 2:00 p.m. ET
Presentation Location: Presentation Room 3
A link to the recording of the presentation will be available on INBS’s Investor Relations website two days after the event.
Management will also be available during the event for one-on-one meetings with the investment community. To schedule a meeting, please contact your NobleCon representative or KCSA Strategic Communications by emailing This email address is being protected from spambots. You need JavaScript enabled to view it..
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Company Contact:
Intelligent Bio Solutions Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.66 |
Daily Change: | -0.08 -4.34 |
Daily Volume: | 29,778 |
Market Cap: | US$7.960M |
January 31, 2025 January 28, 2025 December 18, 2024 November 26, 2024 November 13, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load